Nicox S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALCOX.PA research report →
About the company
Nicox S. A. is an ophthalmology firm operating both within France and internationally, dedicated to developing treatments that preserve sight and enhance eye health.
- CEO
- Gavin Spencer
- IPO
- 2000
- Employees
- 28
- HQ
- Valbonne, FR
Price Chart
- Market Cap
- $30.17M
- P/E
- -13.72
- P/S
- 1.80
- P/B
- 5.50
- EV/EBITDA
- 1.40
- Div Yield
- 0.00%
- Gross Margin
- 38.99%
- Op Margin
- -81.33%
- Net Margin
- -14.39%
- ROE
- -51.16%
- ROIC
- -163.75%
- Revenue
- $16.77M · 113.41%
- Net Income
- $-2,412,924 · 89.22%
- EPS
- $-0.03 · 92.17%
- Op Income
- $-13,640,939
- FCF YoY
- 0.00%
- 52W High
- $0.65
- 52W Low
- $0.22
- 50D MA
- $0.39
- 200D MA
- $0.37
- Beta
- 0.53
- Avg Volume
- 253.50K
Get TickerSpark's AI analysis on ALCOX.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALCOX.PA coverage
Recent articles, reports, and earnings notes.
No research on ALCOX.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALCOX.PA report →Similar companies
Peers in the same neighborhood.